KRAS and urinary bladder carcinoma: May be known—FAP the precursor lesions will have multiple genetic signatures (all will have APC mutations, mixed KRAS status). DCIS and superficial bladder cancer will have a clear molecular lesion and signature will be available. Basal subtype of bladder cancer represents roughly 20% of bladder cancers but it has a worse prognosis than any of the other subtypes. Its susceptibility to EGFR inhibitors makes it a candidate for an intervention. Its poorer prognosis may allow for higher levels of toxicity which would be otherwise unacceptable